NCT03403374View on ClinicalTrials.gov

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 4, 2018

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions
Homozygous Familial Hypercholesterolemia HoFH
Interventions
DRUG

evolocumab

Administered by SC injection via autoinjector (AI)/pen

Trial Locations (12)

590010

Research Site, Belagavi

380 054

Research Site, Ahmedabad

560 017

Research Site, Bangalore

682 027

Research Site, Kochi

400 007

Research Site, Mumbai

411 005

Research Site, Pune

411 006

Research Site, Pune

110 002

Research Site, New Delhi

110 029

Research Site, New Delhi

110 060

Research Site, New Delhi

110 062

Research Site, New Delhi

226 003

Research Site, Lucknow

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03403374 - Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter